159 related articles for article (PubMed ID: 17635750)
1. Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease.
Wahl PR; Le Hir M; Vogetseder A; Arcaro A; Starke A; Waeckerle-Men Y; Serra AL; Wuthrich RP
Nephrology (Carlton); 2007 Aug; 12(4):357-63. PubMed ID: 17635750
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
3. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.
Wu M; Wahl PR; Le Hir M; Wackerle-Men Y; Wuthrich RP; Serra AL
Kidney Blood Press Res; 2007; 30(4):253-9. PubMed ID: 17596700
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease.
Berthier CC; Wahl PR; Le Hir M; Marti HP; Wagner U; Rehrauer H; Wüthrich RP; Serra AL
Nephrol Dial Transplant; 2008 Mar; 23(3):880-9. PubMed ID: 18042615
[TBL] [Abstract][Full Text] [Related]
5. Altered ATP-sensitive P2 receptor subtype expression in the Han:SPRD cy/+ rat, a model of autosomal dominant polycystic kidney disease.
Turner CM; Ramesh B; Srai SK; Burnstock G; Unwin RJ
Cells Tissues Organs; 2004; 178(3):168-79. PubMed ID: 15655334
[TBL] [Abstract][Full Text] [Related]
6. [Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].
Banković-Calić N; Ogbori MR; Nicman E
Srp Arh Celok Lek; 2002; 130(7-8):251-7. PubMed ID: 12585002
[TBL] [Abstract][Full Text] [Related]
7. Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD).
Fischer DC; Jacoby U; Pape L; Ward CJ; Kuwertz-Broeking E; Renken C; Nizze H; Querfeld U; Rudolph B; Mueller-Wiefel DE; Bergmann C; Haffner D
Nephrol Dial Transplant; 2009 Jun; 24(6):1819-27. PubMed ID: 19176689
[TBL] [Abstract][Full Text] [Related]
8. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease.
Nagao S; Yamaguchi T; Kusaka M; Maser RL; Takahashi H; Cowley BD; Grantham JJ
Kidney Int; 2003 Feb; 63(2):427-37. PubMed ID: 12631108
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
Tao Y; Kim J; Schrier RW; Edelstein CL
J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
[TBL] [Abstract][Full Text] [Related]
10. The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats.
Wang D; Braendstrup O; Larsen S; Horn T; Strandgaard S
APMIS; 2004 Jun; 112(6):358-68. PubMed ID: 15511273
[TBL] [Abstract][Full Text] [Related]
11. A new in vitro bioassay for cyst formation by renal cells from an autosomal dominant rat model of polycystic kidney disease.
Pey R; Bach J; Schieren G; Gretz N; Hafner M
In Vitro Cell Dev Biol Anim; 1999; 35(10):571-9. PubMed ID: 10614866
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of SPARC and its impact on proliferation and apoptosis in ADPKD cyst-lining epithelia.
Wang W; Mei C; Tang B; Zhao H; Xu C; Li Z; Shen X; Fu W; Dai B
Nephrol Dial Transplant; 2006 May; 21(5):1278-88. PubMed ID: 16421164
[TBL] [Abstract][Full Text] [Related]
13. Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease.
Ecder T; Melnikov VY; Stanley M; Korular D; Lucia MS; Schrier RW; Edelstein CL
Kidney Int; 2002 Apr; 61(4):1220-30. PubMed ID: 11918728
[TBL] [Abstract][Full Text] [Related]
14. Renal activity of Akt kinase in obese Zucker rats.
Zdychová J; Kazdová L; Pelikanová T; Lindsley JN; Anderson S; Komers R
Exp Biol Med (Maywood); 2008 Oct; 233(10):1231-41. PubMed ID: 18641049
[TBL] [Abstract][Full Text] [Related]
15. Gene profiling of polycystic kidneys.
Schieren G; Rumberger B; Klein M; Kreutz C; Wilpert J; Geyer M; Faller D; Timmer J; Quack I; Rump LC; Walz G; Donauer J
Nephrol Dial Transplant; 2006 Jul; 21(7):1816-24. PubMed ID: 16520345
[TBL] [Abstract][Full Text] [Related]
16. Focal overexpression of collagen IV characterizes the initiation of epithelial changes in polycystic kidney disease.
Schäfer K; Bader M; Gretz N; Oberbäumer I; Bachmann S
Exp Nephrol; 1994; 2(3):190-5. PubMed ID: 7922272
[TBL] [Abstract][Full Text] [Related]
17. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats.
Wang X; Zhang S; Liu Y; Spichtig D; Kapoor S; Koepsell H; Mohebbi N; Segerer S; Serra AL; Rodriguez D; Devuyst O; Mei C; Wüthrich RP
Kidney Int; 2013 Nov; 84(5):962-8. PubMed ID: 23715121
[TBL] [Abstract][Full Text] [Related]
18. Hereditary error in epidermal growth factor prohormone metabolism in a rat model of autosomal dominant polycystic kidney disease.
Lakshmanan J; Eysselein V
Biochem Biophys Res Commun; 1993 Dec; 197(3):1083-93. PubMed ID: 8280123
[TBL] [Abstract][Full Text] [Related]
19. Increased epithelial cell proliferation and abnormal extracellular matrix in rat polycystic kidney disease.
Ramasubbu K; Gretz N; Bachmann S
J Am Soc Nephrol; 1998 Jun; 9(6):937-45. PubMed ID: 9621276
[TBL] [Abstract][Full Text] [Related]
20. Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats.
Cowley BD; Ricardo SD; Nagao S; Diamond JR
Kidney Int; 2001 Dec; 60(6):2087-96. PubMed ID: 11737583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
